LDS/Medical Tests/Fentanyl, Serum

Fentanyl, Serum

Fentanyl is a synthetic opioid that was introduced in 1960. Fentanyl is an extremely fast-acting opioid agonist that is approximately 100 times more potent in its therapeutic effect than morphine. Fentanyl has a tendency, when abused, to produce severe respiratory depression and heightened euphoria. Fentanyl can be administered in a sublingual spray, nasal spray, tablets, lollipop/lozanges, injectable and infused solutions, or transdermal patch. With the patch, therapeutic effects require approximately 6 hours, and may take up to 24 hours to be fully realized. For all other formulations, therapeutic effects occur within minutes. Access in the US is limited by the FDA’s REMS program. Fentanyl is rapidly metabolized to norfentanyl and hydroxyl metabolites. The half-life of fentanyl is 3-12 hours. Duration of therapeutic effect depends on the specific formulation administered. Fentanyl abuse has become very popular among healthcare workers due to the euphoric nature of its effects and its availability.

 Approximately 85% of a single fentanyl dose is eliminated in the urine over 3-4 days, primarily as norfentanyl.

Common side effects: euphoria, sedation, mental clouding, amnesia, hostility, irritability, and vivid or disturbing dreams. Overdose effects include respiratory depression, nausea, vomiting, constipation, hypothermia, seizure, hypotension, coma, and possible death.

Codeine and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Therapeutic monitoring
  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result for fentanyl and/or norfentanyl indicates only the presence of fentanyl and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method.

Therapeutic Level: 10-100 ng/ml

Toxic level: >200 ng/ml

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

     

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). Immunoassays for fentanyl are generally designed to cross-react with norfentanyl. Targeted assays can distinguish between fentanyl and norfentanyl.

Urine

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

Ambient 5 days Refrigeration 7 days Frozen 30 days

Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA:Biomedical Publications; 2002.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.